Vanguard Total International Bond Index Fund ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.89, while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | VRTX | |
|---|---|---|
52-Week High | $49.91 | $529.65 |
52-Week Low | $47.57 | $376.62 |
Market Cap | — | $134.25B |
Sector | — | Health |
Enterprise Value | — | $128.37B |
Trailing returns across standard periods
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →